Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IVX 411

Next Previous
X
Search
Drug Profile

IVX 411

Alternative Names: COVID-19 VLP vaccine - Icosavax; IVX-411

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Washington
  • Developer Icosavax; Seqirus
  • Class COVID-19 vaccines; Protein vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Coronavirus spike glycoprotein modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 19 Oct 2022 Interim top-line adverse events and immunogenicity data from a phase I/II trial in COVID-2019 infections (Prevention) presented at the ID Week (IDW-2022)
  • 25 Mar 2022 Top-line safety and immunogenicity data from a phase I/II trial in COVID-2019 infections (Prevention) released by Icosavax
  • 09 Jun 2021 Phase I/II clinical trials for COVID-2019 infections (Prevention, In the adults, In the elderly) in Australia (IM) (ACTRN12621000738820)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top